
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction | Science science.org/doi/10.1126/scie…
✓T like Trouble @KRASKickers Too spunky for #LungCancer Kicking cancer’s #KRAS #research #advocate #survivor #hope ❤️🤣🙏#biomarker NO #KRASholes

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction | Science science.org/doi/10.1126/scie…

Big Ben of thoracic oncology teaches us after recent failures how to make ADCs great again! Upfront combinations of Dato-dxd w pembro+_ platinum in TROPION Lung02 seem feasible although some AE concerns- activity enriched by NMR QCS and might be the way forward to enrich patient population of benefit @benlevylungdoc

Advances in ctDNA assays enhance early relapse detection in lung cancer — sessions at #ASCO25 will showcase these data and I look forward to seeing the updates on MRD! @PennMDForum @PennMedicine @PennCancer @ASCO @OncoAlert @MartinReck2

Online now concurrent with the #AACR25 oral presentation by Cancer Discovery Early Career Award Winner @Sandra_Misale: Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations brnw.ch/21wSh8j

SY08 - Developments in RAS Signaling Inhibition: Bench to Bedside Frank McCormick! Piro Lito! Sandra Misale! abstractsonline.com/pp8/#!/2… @KRASKickers @Sandra_Misale

Dr Shokat talk at opening plenary at #AACR25 on how progress in studying #KRAS, historically known as ‘undruggable’, led to developing drugs to target it. Never say never… The impossible CAN be possible! @KRASKickers #LCSM

Thank you for all that it takes to make this happen! #AACR25 hardworking folks we appreciate you !

Congratulations to @Sandra_Misale, PhD, recipient of the 2025 Cancer Discovery Early Career Award, which recognizes the outstanding contributions of #earlycareer investigators. Learn more: brnw.ch/21wSfdp #AACR25 @HopkinsMedicine @hopkinskimmel @AACR

Brilliant presentation by Katie Arbour @MSKCC of the RMC9805 data!#AACR25 @MDAndersonNews

#AACR25 session today ND01 - AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors A FIH study with AMG 410 is planned CRC, PDAC, NSCLC) G12D, G12V, G13D abstractsonline.com/pp8/#!/2… @KRASKickers

conclusion slide many slides of interest including KRAS targets & their responses as well as combinatorial options (EGFRi & anti-PD-1) @KRASKickers #AACR25

So proud of you & the #KickKRAS progress you’re making!! @KRASKickers

Thanks to @KRASKickers for te opportunity to discuss about biomarkers with their community! Thanks @TerriConneran for the fantastic discussion! Testing Testing Testing! @OSUCCC_James @OhioStateMedOnc @isliquidbiopsy

Very exciting early signals for JYP0322 at #AACR25 — especially promising that no DLTs were observed and MTD wasn't reached during dose escalation. Also interesting that patients with stable CNS metastases were eligible — curious to see more on intracranial outcomes as data matures! 🧠✨ #LCSM

This is the way to start the day!! #AACR25 Doc (Shokat ) that found the Pocket to kick the first KRAS .. #KRASKicker 💥

Targeted protein degradation for cancer therapy | Nature Reviews Cancer nature.com/articles/s41568-0…